TAVR in 2023: Who Should Not Get It?. [Review]

MedStar author(s):
Citation: American Journal of Cardiology. 193:1-18, 2023 04 15.PMID: 36857839Institution: MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment: Advanced Cardiac Catheterization Research Fellowship | Interventional Cardiology FellowshipForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Aortic Valve Stenosis | *Heart Valve Prosthesis | *Heart Valve Prosthesis Implantation | *Transcatheter Aortic Valve Replacement | Aortic Valve Stenosis/et [Etiology] | Aortic Valve Stenosis/su [Surgery] | Aortic Valve/su [Surgery] | Heart Valve Prosthesis Implantation/ae [Adverse Effects] | Heart Valve Prosthesis/ae [Adverse Effects] | Humans | Risk Factors | Transcatheter Aortic Valve Replacement/ae [Adverse Effects] | Treatment Outcome | Year: 2023Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0002-9149
Name of journal: The American journal of cardiologyAbstract: Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023. Copyright © 2023 Elsevier Inc. All rights reserved.All authors: Aladin A, Ben-Dor I, Bhogal S, Cohen JE, Reardon MJ, Rogers T, Satler LF, Shults CC, Waksman R, Weissman G, Wermers JP, Yakubov SJFiscal year: FY2023Digital Object Identifier: Date added to catalog: 06/01/2023
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 36857839 Available 36857839

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006

Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023. Copyright © 2023 Elsevier Inc. All rights reserved.

English

Powered by Koha